Literature DB >> 33723723

Drug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment Outcomes.

Yurong Song1, Chenxi Li1, Guangzhi Liu1, Rui Liu1, Youwen Chen1, Wen Li1, Zhiwen Cao1, Baosheng Zhao2, Cheng Lu3, Yuanyan Liu4.   

Abstract

Drug metabolism is a critical process for the removal of unwanted substances from the body. In humans, approximately 80% of oxidative metabolism and almost 50% of the overall elimination of commonly used drugs can be attributed to one or more of various cytochrome P450 (CYP) enzymes from CYP families 1-3. In addition to the basic metabolic effects for elimination, CYP enzymes in vivo are capable of affecting the treatment outcomes in many cases. Drug-metabolizing CYP enzymes are mainly expressed in the liver and intestine, the two principal drug oxidation and elimination organs, where they can significantly influence the drug action, safety, and bioavailability by mediating phase I metabolism and first-pass metabolism. Furthermore, CYP-mediated local drug metabolism in the sites of action may also have the potential to impact drug response, according to the literature in recent years. This article underlines the ability of CYP enzymes to influence treatment outcomes by discussing CYP-mediated diversified drug metabolism in primary metabolic sites (liver and intestine) and typical action sites (brain and tumors) according to their expression levels and metabolic activity. Moreover, intrinsic and extrinsic factors of personal differential CYP phenotypes that contribute to interindividual variation of treatment outcomes are also reviewed to introduce the multifarious pivotal role of CYP-mediated metabolism and clearance in drug therapy.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33723723     DOI: 10.1007/s40262-021-01001-5

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  158 in total

1.  Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2008-07-30       Impact factor: 7.853

2.  Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53.

Authors:  Ido Goldstein; Noa Rivlin; Or-yam Shoshana; Osnat Ezra; Shalom Madar; Naomi Goldfinger; Varda Rotter
Journal:  Carcinogenesis       Date:  2012-10-10       Impact factor: 4.944

3.  Impact of hepatic malignancy on CYP3A4 gene expression.

Authors:  Bridget N Fahy; Tao Guo; Romi Ghose
Journal:  J Surg Res       Date:  2012-06-21       Impact factor: 2.192

4.  Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins.

Authors:  H H J Gerets; K Tilmant; B Gerin; H Chanteux; B O Depelchin; S Dhalluin; F A Atienzar
Journal:  Cell Biol Toxicol       Date:  2012-01-19       Impact factor: 6.691

5.  Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity.

Authors:  Y Xiao; M Ge; X Xue; C Wang; H Wang; X Wu; L Li; L Liu; X Qi; Y Zhang; Y Li; H Luo; T Xie; J Gu; J Ren
Journal:  Kidney Int       Date:  2008-03-26       Impact factor: 10.612

6.  How important is intestinal cytochrome P450 3A metabolism?

Authors:  Antonius E van Herwaarden; Robert A B van Waterschoot; Alfred H Schinkel
Journal:  Trends Pharmacol Sci       Date:  2009-03-28       Impact factor: 14.819

Review 7.  Recent Structural Insights into Cytochrome P450 Function.

Authors:  F Peter Guengerich; Michael R Waterman; Martin Egli
Journal:  Trends Pharmacol Sci       Date:  2016-06-04       Impact factor: 14.819

Review 8.  CYP-mediated drug metabolism in the brain impacts drug response.

Authors:  Douglas M McMillan; Rachel F Tyndale
Journal:  Pharmacol Ther       Date:  2017-10-10       Impact factor: 12.310

9.  Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.

Authors:  C Martínez; E García-Martín; R M Pizarro; F J García-Gamito; J A G Agúndez
Journal:  Br J Cancer       Date:  2002-09-09       Impact factor: 7.640

Review 10.  Survey of Human Oxidoreductases and Cytochrome P450 Enzymes Involved in the Metabolism of Xenobiotic and Natural Chemicals.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2014-12-19       Impact factor: 3.739

View more
  3 in total

1.  Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting.

Authors:  Camille Lenoir; Jean Terrier; Yvonne Gloor; Pauline Gosselin; Youssef Daali; Christophe Combescure; Jules Alexandre Desmeules; Caroline Flora Samer; Jean-Luc Reny; Victoria Rollason
Journal:  J Pers Med       Date:  2022-03-24

Review 2.  Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.

Authors:  Ramón Cacabelos; Vinogran Naidoo; Lola Corzo; Natalia Cacabelos; Juan C Carril
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

3.  Potent Inhibition of Human Cytochrome P450 3A4 by Biflavone Components from Ginkgo Biloba and Selaginella Tamariscina.

Authors:  Bo Wang; Chao Shi; Lei Feng; Wei Pan; Xiang-Ge Tian; Cheng-Peng Sun; Chao Wang; Jing Ning; Xia Lv; Yan Wang; Qian-Hui Yuan; Rui-Xuan Guan; Hou-Li Zhang; Xiao-Chi Ma; Tong-Hui Ma
Journal:  Front Pharmacol       Date:  2022-02-28       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.